Relapse-related candidate genes and their clinicopathological connections of diffuse large B cell lymphoma
10.3760/cma.j.cn112151-20240920-00620
- VernacularTitle:弥漫大B细胞淋巴瘤复发相关基因及与临床病理特征的关系
- Author:
Yuxi GONG
1
;
Yefan YANG
;
Shuning SUN
;
Rumeng BAI
;
Shuaishuai ZHUO
;
Yang SHAO
;
Kaihua LIU
;
Yuqian SHI
;
Zhihong ZHANG
Author Information
1. 南京医科大学第一附属医院病理科，南京 210029
- Publication Type:Journal Article
- Keywords:
Recurrence;
Lymphoma, large B-cell, diffuse;
DNA mutational analysis;
FAT4;
PIM1
- From:
Chinese Journal of Pathology
2025;54(4):348-353
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the relapse-related genes and their clinicopathological connections of diffuse large B cell lymphoma (DLBCL).Methods:Targeted panel sequencing was conducted on 32 eligible DLBCL samples; the patients were diagnosed, treated, and went into complete remission at the First Affiliated Hospital of Nanjing Medical University from January 2015 to December 2019, including 14 cases with recurrence (relapsed group) and 18 cases with long-term complete remission of over five years (remission group). Clinical and pathological data were further reviewed. Fisher′s exact test was employed to compare the differences in clinicopathological characteristics and mutation patterns between the two groups.Results:Among the 32 patients, there were 18 males and 14 females, with a male to female ratio of 1.3∶1.0 and a median age of 53 (45.5, 67.0) years. In the relapsed group, PIM1 (11/14), KMT2D (7/14), PRDM1 (6/14), MYD88 (6/14), DTX1 (6/14) emerged as the most frequently mutated genes. In the remission group, while recurrent PIM1, KMT2D and MYD88 mutations were also observed, the TP53 gene exhibited the highest mutation frequency (6/18). Compared to the remission group, relapsed group showed elevated mutation frequencies of PIM1 ( P=0.013) and FAT4 ( P=0.010), alongside a reduced incidence of TP53 mutations. In all 32 patients, DLBCL with CD79B, CCND3, DTX1, KMT2D and PRDM1 mutations demonstrated a propensity towards advanced clinicopathologic stage. Conclusions:Relapsed DLBCL has distinctive clinicopathological and genetic features. PIM1 and FAT4 may be served as potential biomarkers for screening relapsed DLBCL-NOS and as targets for novel therapeutic strategies.
